Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Platelet-rich plasma not suitable for routine use in clinical practice

Research

Platelet-rich plasma not suitable for routine use in clinical practice.

Image courtesy of Shutterstock

In a new paper published in the British Medical Journal, Dr David Keene and Professor Keith Willett highlight that routine use of platelet-rich plasma (PRP) in clinical practice for musculoskeletal soft tissue injuries cannot be recommended given the lack of high quality clinical evidence supporting its efficacy.

PRP are prepared from a patient's own blood and have become increasingly popular in sports medicine and orthopaedic practice as treatment for muscle, tendon, and ligament injuries. However, there is insufficient evidence to support the use of PRP and more research is needed to establish its efficacy and how it compares to other active interventions.

Read more (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences)

Similar stories

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.